Most material SEC filings — August 12, 2026

Hashdex Asset Management announced closure and liquidation of the Hashdex Bitcoin ETF (NYSE Arca: DEFI), a $14.7M fund as of July 30, 2026. The sole series of Hashdex Commodities Trust will cease trading August 17, 2026, begin asset liquidation August 18, 2026, and distribute remaining net assets to shareholders on or about August 24, 2026. The sponsor cited low AUM relative to operating expenses as the reason for termination.

On June 25, 2026, Bio-Techne agreed to be acquired by Merck KGaA, Darmstadt, Germany for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion. The transaction was announced during the company's Q4 FY2026 earnings (ended June 30, 2026), in which Bio-Techne reported flat full-year revenue of $1.2 billion, GAAP EPS of $1.16 (vs. $0.46 prior year), and adjusted EPS of $1.93 (flat vs. $1.92 prior year). Bio-Techne has ceased holding investor conference calls due to the pending transaction.

ENvue Medical (market cap ~$7.3M) entered into two agreements on August 12, 2026: (1) a Common Shares Purchase Agreement with an unnamed Liechtenstein-based investor, providing up to $50M in committed capital through a variable-price VWAP mechanism (limited to 19.99% of shares outstanding absent shareholder approval); and (2) a Second Amendment to its Series H Preferred Stock purchase agreement, extending the Preferred Holders' additional investment rights by 36 months with a mandatory $10M annual minimum (reduced dollar-for-dollar by proceeds from the ELOC or Form S-3 shelf). The company commits 40% of registered offering proceeds to redeem outstanding Series X Preferred Stock.

CID HoldCo (DAIC) received a delisting notice from Nasdaq on August 6, 2026, for failing to maintain the $50M minimum market value of listed securities (MVLS) requirement. The company has announced intention to appeal by requesting a hearing before a Nasdaq Hearings Panel (by August 13, 2026 deadline with $20,000 fee); the stock remains listed pending the hearing outcome. The company previously regained compliance with the minimum bid price requirement ($1.00+) on June 23, 2026, but failed to regain MVLS compliance by the August 4 deadline.

Cycurion, Inc. (NASDAQ: CYCU) announced its hearing before the Nasdaq Hearings Panel is scheduled for August 20, 2026, at 10:00 a.m. ET. The company's stock remains listed and trading on Nasdaq Capital Market under symbol CYCU; the timely hearing request stayed delisting action pending the Panel's final written decision. No specific compliance violations, financial figures, or remediation details were disclosed in this update.

On August 7, 2026, Capstone Holding Corp. (public market cap ~$1.4M) filed an 8-K disclosing Item 4.02: non-reliance on previously issued financial statements or audit report. No specific dollar amounts, restatement details, affected periods, or root causes are stated in the filing header or document list provided. The filing references XBRL exhibits but those substantive details are not included in this excerpt.

Arbutus received $178.4M in July 2026 as its share of a $950M noncontingent settlement from Moderna (with potential $1.3B contingent payment pending appellate ruling). The company plans to return up to $230M to shareholders via buybacks starting Q3 2026. Additionally, Arbutus filed three international patent lawsuits against Pfizer/BioNTech over LNP technology, and achieved FDA alignment on imdusiran Phase 2b trial design for chronic hepatitis B.

Splash Beverage Group (NYSE American: SBEV, market cap ~$6.5M) announced on August 12, 2026, that it will rebrand to Endovia Health Sciences effective August 24, 2026, with new ticker symbol EDVA. The pivot shifts the company from legacy beverage to a cannabinoid health sciences platform with three stated divisions: commercial pharmaceutical assets, FDA-regulated human/veterinary therapeutics, and consumer wellness beverages. The filing names Interim CEO Brady Cobb and references prior acquisitions of pharmaceutical IP and international partnerships over the past six months, but discloses no specific deal amounts, share counts, or financial metrics.

Fusemachines and Brazilian firm Qintess Holding signed a Master License and Services Agreement (effective August 10, 2026) with a $6.5M minimum committed services spend over three years. Fusemachines will issue up to 1,250,000 common shares to Qintess in three tranches: 750,000 shares immediately (Tranche 1); 250,000 shares at year 2 if $4.5M spent (Tranche 2); 250,000 shares at year 3 if full $6.5M spent (Tranche 3). Agreement includes prepayment milestones (min. $500K by 6 months, $1M by 12 months, $2M by 24 months) and registration rights requiring S-1 filing within 60 days.

Greenland Energy Co received notice from JV partner 80 Mile plc that the Government of Greenland has determined the project requires more extensive regulatory review than initially expected. The targeted permit timeline has been pushed from an unspecified earlier date to winter 2027. The company states it will use the delay to refine planning and logistics for its Jameson Land Basin onshore drilling campaign, with further updates to shareholders forthcoming.

Liquidia reported Q2 2026 net product sales of $170.4M (up 31% QoQ), net income of $74.7M, and adjusted EBITDA of $96.3M—the fourth consecutive quarter of rising profitability. As of July 31, 2026, ~5,900 unique prescriptions and 5,000+ patients started treatment since YUTREPIA launch in June 2025; >1,100 prescribers active, 30% with ≥5 referrals each. Cash increased $61.4M to $284.2M in Q2. Company is advancing 10 clinical studies for YUTREPIA and investigational L606 across PAH, PH-ILD, and new indications.

Fervo Energy completed its IPO in May 2026, raising approximately $2.2 billion in gross proceeds (including full over-allotment exercise). The company reported Q2 2026 net loss of $55.9 million and operating loss of $28.7 million, with capex of $226.5 million in Q2 and guidance of $850–$900 million for H2 2026. Fervo raised its long-term development target by 100 megawatts to 1.1 gigawatts by 2030, advanced Cape Station Phase I toward commercial operation (GeoBlock 1 first power targeted Q4 2026), and set a company drilling record with the Sawtooth 7 well.

On August 10, 2026, Capstone Holding Corp. reduced the conversion price of senior secured convertible notes held by 3i, LP from multiple prior prices ($0.75, $0.57, $1.10) to a uniform $0.2949 effective immediately. The adjustment applies to $250,372 principal under the July 2025 Note and $1,650,388 principal under the October 2025 Note, making conversion significantly more attractive to the investor. Additionally, the company granted 2.8M+ restricted shares to six executives under a new 2025 Stock Incentive Plan with base dilution protection provisions extending through March 2031.

On May 18, 2026, Beacon Bank Trust waived noncompliance by TotalStone LLC and related subsidiaries (Northeast Masonry Distributors, TotalStone Properties, CS Purchase Holdings, Carolina Stone Holdings, Carolina Stone Distributors) with the Cash Flow Coverage Ratio covenant for the 12-month period ending March 31, 2026, in exchange for a $7,000 noncompliance fee. The underlying Revolving Credit, Term Loan and Security Agreement originated December 20, 2017 and was most recently amended on December 19, 2025.

Altimmune announced initiation of the global PERFORMA Phase 3 trial in MASH (metabolic dysfunction-associated steatohepatitis) with 52-week data expected in 2029, positive topline results from the RECLAIM Phase 2 trial in alcohol use disorder showing statistically significant reduction in heavy drinking days, and completion of patient enrollment in the RESTORE Phase 2 trial in alcohol-associated liver disease. The company holds $519 million in cash, cash equivalents, and investments as of June 30, 2026, bolstered by a $225 million gross proceeds public offering completed in April 2026. Q2 2026 net loss was $22.8 million (vs. $22.1 million in Q2 2025); R&D expenses were $18.7 million.

Definium announced positive topline results from the Phase 3 Voyage study of DT120 ODT (lysergide 100 µg) in generalized anxiety disorder (n=214, 1:1 randomization vs. placebo). Primary endpoint: HAM-A score improved 5.4 points more than placebo at Week 12 (p<0.0001, Cohen's d=0.81). All key secondary endpoints also met. Safety profile consistent with prior studies; no new safety signals, no suicidality signal. This is Definium's second positive Phase 3 readout (first was Emerge in MDD in June). Panorama Phase 3 results in GAD expected September 2026.

FlyExclusive reported Q2 2026 consolidated revenue of $111 million (+22% YoY) with $4.2 million positive Adjusted EBITDA (vs. negative in prior year), a $9.4M sequential improvement from Q2 2025. The company reduced its fleet by 6% while increasing flight hours 8%, eliminated 32 non-performing aircraft, improved dispatch availability by 1,013 basis points, and reduced long-term notes payable by $94 million since 2024. Gross margin expanded 539 basis points to 20%, and Adjusted EBITDA margin improved 954 basis points YoY.

NeOnc Technologies (NTHI; $67.9M market cap) announced positive Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma (24 patients, intent-to-treat). Primary endpoint met: 6-month progression-free survival 48.9% (95% CI 26.3–68.1) vs pre-specified 20% standard-of-care benchmark (p=0.0047, one-sided). Median overall survival 26.09 months from recurrence (vs historical 6–9 month salvage benchmark); 86.7% alive at 6 months, 60.9% at 12 months. Five of 24 patients remain on treatment; no major toxicities reported. Company plans Type B FDA meeting to align on registrational (Phase 3) path.

Dyadic reported Q2 2026 revenue of $961,138 (down 0.6% YoY) and net loss of $2,123,884 ($0.06 per share). Cash declined 44% from $8.6M (Dec 2025) to $4.8M (June 2026). The company announced initial product shipments across recombinant proteins, partnerships with Proliant Health Biologicals, Fermbox Bio, and Inzymes, and Gates Foundation-funded antibody programs, but management disclosed substantial doubt about going-concern status for 12 months post-June 30, 2026.

Spruce Biosciences raised $5.5M via private stock purchase (Regulation D Rule 506(b)) from Cure Sanfilippo Foundation and National MPS Society (unspecified amounts per purchaser; Exhibit A redacted). Adrian Quartel hired as Chief Medical Officer effective July 27, 2026, at $512,300 annual base salary plus 40% target bonus and 13,000 RSU award vesting over four years. Proceeds designated exclusively for expanded-access enzyme replacement drug substance and product manufacturing.

On July 22, 2026, Monopar initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease treatment, with completion expected within months. The candidate received Rare Pediatric Disease designation on June 30, 2026, potentially qualifying for a Priority Review Voucher upon approval. Q2 2026 net loss was $5.3M ($0.62/share) vs. $2.5M ($0.35/share) in Q2 2025; cash position was $134.3M as of June 30, 2026, with runway through at least December 31, 2027.

Natural Gas Services Group completed the acquisition of Flatrock for approximately $119M ($108.9M cash + $10M stock) in June 2026, adding ~87,000 rented horsepower and materially increasing electric motor drive capabilities (20% vs. 7% pre-acquisition). Q2 2026 saw record results: rental revenue $49.4M (+25% YoY), adjusted EBITDA $25.1M (+27.4% YoY), and 88.3% horsepower utilization. Full-year 2026 adjusted EBITDA guidance raised from $92.5-97.5M to $103-108M; growth CapEx raised to $60-80M. Leverage at quarter-end was 2.77x with $172M unused commitments.

Annexon entered a $200M credit facility with Oxford Finance LLC (initial $50M drawn at closing), extending runway to 2028. Lead program tanruprubart shows positive Phase 3 data in GBS with BLA submission expected Q4 2026. Vonaprument Phase 3 ARCHER II trial (659 patients, GA indication) added Month 24 dual primary endpoint alongside Month 15 primary endpoint (both expected Q4 2026 and Q3 2027 respectively), with Month 15 on track. Third program ANX1502 (oral C1 inhibitor) POC data expected Fall 2026. Q2 2026: net loss $55.3M ($0.28/share) vs. $49.2M ($0.34/share) prior year; cash position $209.2M.

Kontoor Brands raised full-year 2026 adjusted EPS guidance from $5.15–$5.25 to $5.25–$5.35 (27–29% growth), driven by Q2 revenue of $584M (+19% YoY, including $114M Helly Hansen contribution) and adjusted gross margin expansion to 53.8% (+710 bps). The company expects to deploy $400M of proceeds from the planned Lee business divestiture (closing Q4 2026) into an accelerated share repurchase agreement, with remaining proceeds toward debt reduction. Adjusted gross margin guidance raised to 49.8–50.0% for full year (+330–350 bps), and the company plans $25M incremental growth investments.

Lexeo Therapeutics (market cap ~$216.5M) finalized and initiated SUNRISE-FA 2, a pivotal open-label study for LX2006 in Friedreich ataxia cardiomyopathy in June 2026, with first patient enrolled and topline data expected in H2 2027 and BLA filing in H1 2028. The company also received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for LX2020 in PKP2 arrhythmogenic cardiomyopathy based on interim clinical data. Cash position stands at $234.2M, providing runway into 2028. Q2 2026 net loss was $25.9M ($0.30/share); R&D expenses were $19.0M, up from $14.7M YoY.

Cypherpunk increased Zcash holdings to 323,394.38 ZEC (1.92% of circulating supply) with a $46M unrealized gain in Q2 2026 as ZEC price rose from $243.35 to $400.09; added Dev Ojha (Valar Group founder) as advisor. Subsidiary Leap Therapeutics published Phase 2 DeFianCe results showing sirexatamab benefit correlates with DKK1-high biomarker subgroup; FDA aligned on Phase 3 trial design (~270 patients, dual endpoints for accelerated and full approval). Leap initiated strategic process to finance or partner sirexatamab advancement; no transaction timetable set.

Applied Aerospace & Defense (NYSE: AADX) completed a $683.0M IPO in June 2026, raising $635.6M in net proceeds via sale of 34.2M shares at $20/share. Q2 2026 revenue reached $167.3M (+47.4% YoY), with record Adjusted EBITDA of $36.4M (+38.5% YoY). However, GAAP net loss was $154.0M in Q2, primarily driven by $110.1M share-based compensation and $5.2M IPO transaction costs. Contract backlog stands at $1.13B; FY2026 guidance: revenue $670–690M, Adjusted EBITDA $150–155M.

Chief Executive Officer Huang Jack Jiajia (COE) bought 396K shares (~$7.7M) on the open market (1.1% of holdings). Open-market insider purchase — historically a bullish signal.

Spruce Biosciences reported Q2 2026 results with cash of $96.3M (vs. $48.9M end-2025), up ~97% following a financing. Cure Sanfilippo Foundation and National MPS Society invested $5.5M combined to fund an Expanded Access Program. The company plans BLA submission for TA-ERT (MPS IIIB therapy) in Q4 2026 and will initiate the TrAnsform confirmatory study same quarter. Two senior clinical hires (Chief Medical Officer Adrian Quartel and VP Clinical Development Jessica Cohen Pfeffer) joined to support regulatory and commercial readiness.

T1 Energy Inc. acquired foundational TOPCon solar patents and IP from Evervolt for $135 million total consideration ($2M upfront cash, $60M in equity July 2026, $73M in three cash tranches Sept-Oct 2026). Separately, T1 signed a 641 MW strategic offtake agreement with Clearway Energy Group for G1_Dallas modules built with domestic G2_Austin cells. T1 also completed a $120 million private placement of 4.75% convertible senior notes due 2031 in July 2026 to bridge G2_Austin Phase 1 funding (total Phase 1 capex now $510M with 20% contingency). Q2 2026 net sales: $250.1M; net loss from continuing ops: $(36.9)M; Adjusted EBITDA: $10.7M (including $24.4M tariff refunds); G1_Dallas production: 935 MW.

Acumen Pharmaceuticals reported Q2 2026 financial results with cash, cash equivalents, and marketable securities of $110.2M as of June 30, 2026 (down from $128.4M on March 31, 2026). The company expects to report topline results from its ALTITUDE-AD Phase 2 study (n=542 participants) investigating sabirnetug for early Alzheimer's disease in late 2026. Additionally, Acumen nominated two Enhanced Brain Delivery (EBD) candidates (ACU301 and ACU401) for development under its license agreement with JCR Pharmaceuticals, with an IND filing for a lead EBD candidate targeted for mid-2027. R&D expenses decreased to $27.8M in Q2 2026 from $37.1M in Q2 2025, primarily due to reduced manufacturing and CRO costs.

TScan dosed the first patient in Phase 3 ALLOHA-2 trial (topline mid-2028) for TSC-101 treating heme malignancies post-transplant. Reported positive Cohort C Phase 1 data: 90% manufacturing success rate (17/19), 79% complete donor chimerism (11/14 patients), well-tolerated safety profile. Cash position $100.2M (excluding $5.0M restricted) funds operations into Q2 2027; net loss Q2 2026 was $30.4M; began term loan amortization Q4 2026 after missing non-covenant milestones.

Sutro reported Q2 2026 results with $164.3M cash (down from $202.6M in Q1 2026), supporting operations into at least Q2 2028. STRO-004 Phase 1 enrolled 49 patients across dose levels 1–5 mg/kg (completed in 7 months), showing confirmed and ongoing unconfirmed partial responses in pancreatic, head/neck, and lung cancers with favorable tolerability (6% discontinuation rate, mostly grade 1–2 AEs). Dose optimization ongoing between 4–5 mg/kg; maximum tolerated dose not yet defined. STRO-006 (ITGB6-targeting ADC) expected to initiate Phase 1 in Q3 2026; STRO-227 (PTK7-targeting dual-payload ADC) on track for IND submission in 2026. Astellas collaboration yielded $10M milestone in April 2026 for first TROP2-targeting iADC program, now dosing patients in clinic.

Xilio (market cap ~$34.9M) received FDA clearance for IND application of XTX501, a bispecific PD-1/masked IL-2 therapy, with Phase 1 dosing expected in H2 2026 and initial data in H2 2027. The company is advancing two masked T cell engager programs (CLDN18.2 and PSMA+STEAP1) with IND submissions planned for H2 2027. Cash position is $136.0M as of June 30, 2026, with runway into Q1 2028; collaboration revenue from AbbVie and Gilead agreements increased to $18.7M in Q2 2026 vs. $8.1M in Q2 2025; net loss narrowed to $6.4M vs. $15.8M year-over-year.

Unicycive received a June 2026 Complete Response Letter (CRL) for its oxylanthanum carbonate (OLC) NDA citing third-party manufacturing deficiencies (same issues as June 2025 CRL); FDA has assigned a facility inspection to the vendor, with no clinical efficacy or safety concerns raised. As of June 30, 2026, the company holds $61.4M in cash/equivalents/marketable securities and expects runway into 2027; Q2 2026 net loss was $1.7M ($0.06/share) versus $6.5M loss in Q2 2025, driven partly by $8.0M favorable warrant liability adjustment.

Century Therapeutics completed an FDA pre-IND meeting for CNTY-813 (iPSC-derived islet replacement therapy for type 1 diabetes), achieving alignment on nonclinical data, Phase 1 manufacturing process, and clinical trial design. The company reported $197.2M in cash and investments as of June 30, 2026, providing runway into Q1 2029. CNTY-813 IND submission remains on track for 4Q 2026, with clinical data expected in H2 2027; CNTY-308 (CD19-targeted CAR-iT) is expected to enter clinic in 2026.

PodcastOne reported Q1 Fiscal 2027 (ended June 30, 2026) revenue of $16.1M (+8% YoY) and Adjusted EBITDA of $1.6M (+172% or +$1.0M YoY). The company acquired two podcasts (The Magnificent Others with Billy Corgan and Life Happens with Barb and Michelle), reached #6 Podtrac ranking, and delivered 18M+ downloads/streams with 6M unique listeners in June. Shares outstanding increased from 27.3M (March 31, 2026) to 30.1M (June 30, 2026); cash rose from $3.5M to $7.0M.

Capstone reported Q2 2026 revenue of $21.5M (up 67% YoY from $12.9M), gross profit of $6.0M (up 92% from $3.1M), and Stone Business Adjusted EBITDA of $2.0M at 9.4% margin—a $2.9M sequential improvement from Q1 and achievement of guidance. Gross margin expanded 357 bps to 27.9%. Company reaffirmed FY2026 guidance: $72.1M revenue, $18.7M gross profit, $3.8M Adjusted EBITDA. New location opens August 17; Eldorado Stone reached 81 dealers in 17 states; AI operating system live since April.

XCF Global announced its first commercial renewable diesel sales from New Rise Renewables Reno facility to Tartan Oil LLC (a Berkshire Hathaway subsidiary) in August 2026. The facility began production in July 2026 and operates under a definitive commercial framework with BGN for feedstock and logistics. XCF expects to increase volumes toward the facility's 38 million gallon per year nameplate capacity, but no specific volumes, pricing, or revenue amounts are disclosed.

Sysco provided FY2027 guidance expecting 6-7% sales growth (including ~2% from 53rd week and 1.5-2% inflation) and 9-11% adjusted EPS growth, driven by ~$100M in cost savings from AI and tech initiatives, USFS segment profit growth, and double-digit international profit growth. The company expects to return ~$1B in dividends and targets 2.5% local case growth. Jetro Restaurant Depot acquisition remains pending with pro forma benefits: combined company projects ~20% revenue increase, ~45% adjusted EBITDA increase, ~55% FCF increase, 1.5x mid-to-high single-digit Year 1 EPS accretion, and low-to-mid teens Year 2 accretion; net leverage expected 4.5x at close, improving to 2.75x long-term, with $250M annual net cost synergies.